The absence of meaningful revenue renders traditional valuation metrics like P/E or EV/EBITDA entirely inapplicable to the current business model. Investors should recognize that the current market capitalization is essentially a binary bet on the NEPTUNE trial outcome rather than a reflection of existing operational performance or asset-based value.

The persistent negative returns on invested capital are a direct consequence of the massive R&D burn required to support the Niyad platform without any offsetting commercial income. This trend suggests that until the company achieves regulatory approval and subsequent market penetration, capital efficiency will remain structurally impaired by the necessity of funding non-productive clinical assets.

The liquidity position is highly sensitive to the company's burn rate, and the decline in cash reserves suggests that the current buffer is likely to be exhausted well before commercialization can occur. Investors should monitor the cash runway closely, as the lack of operational cash flow makes the firm entirely dependent on external capital markets to maintain its going-concern status.